Anal cancer treatment regimen considerations for the COVID-19 era: In regard to Tchelebi et al
Radiother Oncol
.
2020 Oct:151:56-57.
doi: 10.1016/j.radonc.2020.07.028.
Epub 2020 Jul 22.
Authors
Sonal S Noticewala
1
,
Ethan B Ludmir
1
,
Cathy Eng
2
,
Emma B Holliday
1
,
Bruce D Minsky
1
,
Van K Morris
3
,
Prajnan Das
4
Affiliations
1
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States.
2
Department of Gastrointestinal Oncology, Vanderbilt-Ingram Cancer Center, Nashville, United States.
3
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States.
4
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States. Electronic address:
[email protected]
.
PMID:
32710989
PMCID:
PMC7375313
DOI:
10.1016/j.radonc.2020.07.028
No abstract available
Publication types
Letter
Comment
MeSH terms
Anus Neoplasms* / therapy
Betacoronavirus
COVID-19
Coronavirus Infections*
Gastrointestinal Neoplasms*
Humans
Pandemics*
Pneumonia, Viral*
SARS-CoV-2